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15 Gastric cancer is the third most lethal cancer worldwide, and
16 evaluation of the genomic status of gastric cancer cells has
17 not translated into effective prognostic or therapeutic strategies.
18 We therefore hypothesize that outcomes may depend on
19 the tumor microenvironment (TME), in particular, cancer-
20 associated fibroblasts (CAF). However, very little is known about
21 the role of CAFs in gastric cancer. To address this, we mapped
22 the transcriptional landscape of human gastric cancer stroma
23 by microdissection and RNA sequencing of CAFs from
24 patients with gastric cancer. A stromal gene signature was
25 associated with poor disease outcome, and the transcription
26 factor heat shock factor 1 (HSF1) regulated the signature. HSF1
27 upregulated inhibin subunit beta A and thrombospondin 2,
28 which were secreted in CAF-derived extracellular vesicles to the
29 TME to promote cancer. Together, our work provides the
30 first transcriptional map of human gastric cancer stroma and
31 highlights HSF1 and its transcriptional targets as potential
32 diagnostic and therapeutic targets in the genomically stable
33 tumor microenvironment.
34
35 Significance: This study shows how HSF1 regulates a stromal
36 transcriptional program associated with aggressive gastric cancer
37 and identifies multiple proteins within this program as candidates
38 for therapeutic intervention.
39 Introduction
40 Gastric cancer is the fifth most common cancer and the third most
41 lethal cancer, worldwide (1). Recent advances in treatment were made
42 possible due to better classification of gastric cancer subtypes, but the
43 prognosis of advanced gastric cancer remains poor and many patients
44 get diagnosed at an advanced stage of the disease due to limited
45 understanding of the underlying biology (2). There is an urgent need to
47better understand the molecular basis of this disease, and to identify
48biomarkers that may predict outcome and guide therapy.
49Gastric cancer is a heterogeneous disease. Traditionally, anatomical
50location (true gastric vs. gastro-esophageal) and histologic character-
51istics (diffuse vs. intestinal; tubular vs. papillary) have been used to
52classify gastric cancer subtypes (2). Recent advances in molecular
53understanding have enabled classification of gastric cancer into dif-
54ferent subtypes based on chromosomal instability, microsatellite
55instability, genomic stability, presence of Epstein–Barr virus, and
56epithelial–mesenchymal transition (EMT), whichwere associatedwith
57different survival outcomes (3–6). Mutations in CDH1 and KRAS, and
58overexpression of HER2, EGFR, FGFR2, VEGF, were shown to
59contribute to disease progression and correlate with poor out-
60come (7, 8). Despite serving as valuable guides in deciphering the
61complexity of gastric cancer, there has been little success in applying
62these molecular classifiers to treatment stratification and development
63of targeted therapies (3). Prognosis in the clinic is still mostly evaluated
64on the basis of TNMstaging (tumor size, lymphnode involvement, and
65metastasis), and the standard of care for localized gastric cancer is
66surgical intervention combined with chemotherapy (7).
67Increasing evidence over the past decade highlighted the indispens-
68able contribution of the tumor microenvironment (TME) to disease
69progression and treatment resistance (9). The TME is comprised of
70various cell types, including endothelial cells, fibroblasts, macro-
71phages, and lymphocytes, as well as extracellular matrix components
72(ECM; ref. 10). The immune microenvironment of gastric cancer has
73gained increasing attention over the last years, due to its potential effect
74on immunotherapy in patients with highmicrosatellite instability (11).
75Yet little is known about the contribution of cancer-associated fibro-
76blasts (CAF) to gastric cancer progression andmetastasis. CAFs are the
77most abundant cell type in a variety of carcinomas (12). They support
78cancer cells by modifying the ECM, promoting angiogenesis, and
79maintaining a chronic inflammatory state (12–17). In gastric cancer,
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82 accumulation of CAFs is correlated with increased tumor size, inva-
83 sion, and metastasis (18). Recently, the abundance of natural killer
84 cells, endothelial cells, and CAFs was shown to predict chemotherapy
85 benefit in gastric cancer (19). However, the specific genes and molec-
86 ular events contributing to these protumorigenic effects are not well
87 understood. To address this, we set out to map the transcriptional
88 landscape of gastric CAFs. Using laser-capturemicrodissection (LCM)
89 and RNA-sequencing (RNA-seq) of CAFs from patients with gastric
90 cancer, we define a gene-signature associated with poor disease
91 outcome. We characterize this signature using mouse models and
92 co-culture assays, and show that components of this signature are
93 regulated by the master transcriptional regulator heat shock factor 1
94 (HSF1; ref. 20), and secreted fromCAFs via extracellular vesicles (EV).
95 These fibroblast-derived EVs contribute to tumor growth in an HSF1-
96 dependent manner. Together, our work provides a comprehensive
97 map of gastric cancer stromal transcriptionwith potential implications
98 on prognosis and treatment.
99 Materials and Methods
100 Ethics statement
101 Clinical samples and patient data were collected following approval
102 by the Rabin medical center Institutional Review Board (IRB, protocol
103 no. 0297-11-RMC) with full exemption for consent form for anon-
104 ymized samples. Human samples used for MxIF staining were
105 obtained from the Israel National Biobank for Research (MIDGAM;
106 https://www.midgam.org.il/) under IRB no. 6141-19-SMC. These
107 samples were collected from patients who provided written informed
108 consent for collection, storage, distribution of samples, and data for use
109 in future research studies. All animal studies were approved by the
110 Institutional Animal Care and Use Committee (IACUC protocol nos.
111 15310619-2, 15140619-3, 06690820-3).
112 Mice
113 Athymic nude mice were purchased from Harlan Biotech. These
114 mice, the triple-transgenic Lgr5-EGFP-IRES-CreERT2; R26-LSL-rtTA-
115 IRES-EGFP; tetO-GLI2A mice (iLgr5;GLI2A mice; ref. 21), Hsf1 null
116 mice, and their WT littermates (BALB/c  129SvEV, by Ivor J.
117 Benjamin; ref. 22) were maintained under specific-pathogen-free
118 conditions at the Weizmann Institute’s animal facility.
119 Cell lines and primary cell cultures
120 N87 gastric cancer cells were kindly provided by Yosef Yarden
121 (WIS; originally from ATCC). N87 cells were transduced with GFP
122 using a third-generation lentiviral system. MC38 colon cancer cells
123 were kindly provided by Lea Eisenbach (WIS; originally from NCI).
124 MC38 cells were transduced with mcherry-luciferase using a second-
125 generation lentiviral system. Primary MEFs were produced from WT
126 and Hsf1 null mice. HFF cells were purchased from ATCC. MEFs,
127 MC38 cells, and N87 cells were cultured in RPMI (#01-100-1A,
128 Biological Industries) supplemented with 10% FBS (Invitrogen)
129 and P/S (Biological Industries). HFF cells were cultured in DMEM
130 (#01-052-1A, Biological Industries) supplementedwith 15%FBS, 1.5%
131 L-glutamine, and P/S. Cell lines were tested routinely forMycoplasma
132 using EZ-PCR Mycoplasma Test Kit (#20-700-20, Biological Indus-
133 tries). MEFs were used in passage 1. Other cell lines were maintained
134 below passage 25.
135 Laser capture microdissection of human gastric cancer samples
136 LCM cohort patients were selected on the basis of patient outcome
137 data (Supplementary Table S1). Stromal and cancer regions were
138 marked by a trained pathologist blinded to clinical and outcome data
140to include >90% CAFs for stroma and >90% cancer cells for cancer.
141Gastricmuscle, immune islands, and blood vessels were excluded from
142microdissection. FFPE slides were deparaffinized and stained using
143Arcturus Paradise Plus Staining Kit (#KIT0312J; Thermo Fisher
144Scientific) according to the instructions of the manufacturer. Slides
145were left to dry for 5 minutes at RT followed by microdissection using
146the Arcturus (XT) laser microdissection instrument (#010013097,
147Thermo Fisher Scientific). Infrared capture was used to minimize
148RNA damage. CapSure Macro LCM caps (#LCM0211, Thermo Fisher
149Scientific) were used to capture microdissected tissue. To obtain
150sufficient material from these highly degraded RNA samples, we
151performed microdissection from 6 to 10, 5 mm sections per sample.
152Microdissected tissue from each sample was pooled together, and kept
153on dry ice until RNA isolation using the RNeasy FFPE Kit (#73504,
154Qiagen) with one modification—proteinase K digestion at 56C was
155carried out for 1 hour.
156Library preparation, RNA-seq, and analysis of LCM samples
157Libraries were prepared using the SMARTer Stranded Total
158RNA-Seq v2-Pico Input Mammalian Kit (#634415, Takara Bio
159USA) according to the instructions of the manufacturer. Libraries
160were sequenced on Illumina NextSeq 500, at 50M reads for stroma
161and 25M reads for cancer samples, to provide sufficient reads to
162pass quality control filters of RNA-seq. Principal component anal-
163ysis (PCA) was performed on full RNA-seq datasets for each sample
164(for stroma and cancer samples, separately). After calculating
165the first three main PCs (PCA1–3), we used the Robust Mahala-
166nobis distance function to exclude potential outlier samples
167(see GitHub https://github.com/privefl/bigutilsr, and refs. 23–25).
168These robust Mahalanobis distances are approximately Chi-square
169distributed, which enables deriving P values of outliers (Supple-
170mentary Table S2). Because we used three dimensions, we chose a
171P value threshold of 0.00111 (P value <0.01 with Bonferroni
172correction for multiple comparisons), which concluded that patient
1735 is an outlier in PCA2 and PCA3. This patient was removed from
174all downstream analysis. Read counts of the 8 patients were
175normalized and tested for difference using DESeq2 (26). Hierar-
176chical clustering was carried out using Pearson correlation with
177complete linkage and on differentially expressed genes (DEG),
178which were filtered with the following parameters: baseMean >
1795, Padj < 0.1 and |logfoldchange| > 1. Pathway analysis was
180performed using Metascape, significant pathways were determined
181if P < 0.05 and FDR < 0.5. STRING analysis was performed
182including all DEGs.
183CAF isolation and RNA-seq from iLgr5;GLI2A mice
184Gastric cancer was induced in iLgr5;GLI2A mice as described in
185ref. 21. Gastric tumors were harvested post mortem, washed,
186minced, and dissociated using a gentleMACS dissociator and enzy-
187matic digestion with DMEM containing 3 mg/mL collagenase
188A (#11088793001, Sigma Aldrich) and 0.1 mg/mL Deoxyribonu-
189clease I (#LS002007, Worthington) for 20 minutes at 37C. The
190single cell suspension was washed, filtered using 100 mm cell
191strainer, and immunostained. Normal gastric fibroblasts or CAFs
192were collected on the basis of negative selection for ghost dye,
193CD45, EpCAM, and CD31 and positive selection for PDPN. RNA-
194seq was done by MARS-Seq as described in ref. 27. DEGs were
195filtered with the following parameters: baseMean > 5, Padj < 0.01,
196and |logfoldchange| > 3. Pathway analysis was performed using
197Metascape, significant pathways were determined if P < 0.05 and
198FDR < 0.5.
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201 Validation of the patient and iLgr5;GLI2A mouse stromal
202 signatures in independent patient cohorts
203 Patient data from the TCGA, Singapore (GSE15460), KUGH_
204 KUCM (GSE26942), and ACRG cohorts (GSE62254) were down-
205 loaded, individual gene values were transformed to z-scores and the
206 average of all known genes per sample was used to determine scores for
207 the upregulated and downregulated signatures. For the INHBA-
208 THBS1-THBS2 gene-signature individual, gene values were trans-
209 formed to z-scores and the average of genes per sample was deter-
210 mined. Gene symbols were matched through Affymetrix Human
211 Genome U133 Plus 2.0 Array or Illumina HumanHT-12 V4.0 expres-
212 sion bead chip. For patient cohortsGSE15460 andGSE62254, we could
213 match 109 DEGs from the CAF_up_sig and CAF_down_sig; and for
214 GSE26942, we could match 87 DEGs from the CAF_up_sig and
215 CAF_down_sig (out of the total 129 DEGs). For the iLgr5;GLI2A
216 mCAF_up_sig and mCAF_down_sig, 314 DEGs were matched in the
217 GSE15460 and GSE62254 cohorts and 271 DEGs in the GSE26942
218 cohort (out of the total 361 DEGs). Median signature was calculated
219 using patients with complete survival and signature information.
220 Kaplan–Meier (KM) analysis of overall survival with log rank P value
221 was performed for each cancer type or patient cohort on patients
222 stratified by median expression of each of these signatures.
223 HSF1 scoring and analysis
224 Nuclear HSF1 staining in stroma and cancer cells of 72 patients was
225 analyzed by a trained pathologist who was blinded to both patient
226 outcome and clinical data. A scale of 0 to 3 (0–3: low ≤ 1; 1.5 <
227 intermediate ≤ 2; high >2) was set by the pathologist and scores were
228 given on the basis of nuclear staining of HSF1 in stroma and cancer
229 cells (Supplementary Table S1). Tissue samples were obtained from
230 surgical specimens. Patients diagnosed as stage 1 to 3 did not present
231 withmetastases at diagnosis. Eight patients diagnosed as stage 4 gastric
232 cancer with metastases were omitted from further analysis. Overall
233 survival was defined as the time from first diagnosis to death based on
234 the clinical data outlined in Supplementary Table S1. The scores in
235 cancer cells and CAFs showed different distributions. Therefore, for
236 survival analysis of HSF1 activation in cancer cells, patients with low
237 and intermediate scores were combined and compared with patients
238 with high scores, whereas for survival analysis of HSF1 activation in
239 CAFs, patients with high and intermediate scores were combined and
240 compared with patients with low scores (Supplementary Table S1).
241 One patient could not be scored for cancer and for CAF HSF1 due to
242 insufficient tumor tissue and was therefore excluded from all statistical
243 analyses. Two patients could not be scored for CAF HSF1 and were
244 excluded from CAF HSF1 analysis. Stage 2/3 was scored as stage 2 in
245 the final clinical analysis.
246 Co-injection of recombinant activin A and THBS2 with MC38
247 cancer cells into nude mice
248 MC38 (2 105) were incubated with either PBS, 2.5 mg of Activin A
249 (#CYT-146, ProSpec), or 2.5 mg of THBS2 (#1635-T2, R&D Systems)
250 and co-injected in a total volume of 100 mL subcutaneously into Nude
251 mice (Harlan laboratories). Forty-eight hours later, a second dose of
252 2.5 mg recombinant protein was injected. Tumors were measured by
253 caliper for size andmice were sacrificed at day 15 due to high burden in
254 the Activin A group.
255 Co-injection of EVs with MC38 cancer cells into nude mice
256 MC38 cells (2 105) were co-injected with either PBS or 1110 WT
257 orHsf1null EVs subcutaneously intoNudemice (Harlan laboratories).
258 Forty-eight hours later, a second dose (5  109) of EVs was injected.
260Tumors were measured by caliper for size and the mice were sacrificed
261at day 17 due to high tumor burden.
262Data availability statement
263RNA-seq data of iLgr5;GLI2A mice and patient samples were
264deposited in Gene Expression Omnibus (GEO) and can be accessed
265via GSE162301 and GSE165211, respectively. All other data support-
266ing the findings of this study are available from the corresponding
267author on reasonable request.
268Results
269CAFs express a transcriptional program that promotes
270malignancy and correlateswith poor disease outcome in gastric
271cancer
272Gastric CAFs have been attributed protumorigenic effects, however
273the genes contributing to these effects are largely unknown. Therefore,
274we mapped the transcriptome of gastric CAFs in the intratumoral
275stroma by laser capture microdissection (LCM) followed by RNA-seq
276(Supplementary Fig. S1A). We isolated and sequenced CAF-rich
277stromal regions from formalin-fixed paraffin-embedded (FFPE) tumor
278sections of 9 patients with gastric cancer (Supplementary Figs. S1B and
279S1C; Supplementary Table S1), representing favorable (survival) and
280poor prognostic (lethality) outcomes (Supplementary Table S3). PCA
281showed that stromal samples from these patients clustered on basis of
282disease outcome (Fig. 1A; Supplementary Fig. S1D), whereas cancer
283samples from the same patients did not (Fig. 1B; Supplementary
284Fig. S1E). Differential expression analysis of stromal samples (see
285Materials andMethods, Supplementary Table S2; Supplementary Figs.
286S1F and S1G) revealed 129DEGs between favorable and poor outcome
287groups (Fig. 1C; Supplementary Table S3). ECMorganization (involv-
288ing genes such as AEBP1, COL10A1, COL11A1, SPOCK1, THBS2,
289EMILIN1, and TPM2), response to growth factors (INHBA, FGFR1,
290HSPB1), and mesenchymal cell proliferation (LMNA, UACA) were
291the most differentially upregulated pathways in the stroma of
292patients with poor outcome (compared with patients with favorable
293outcome; Fig. 1C; Supplementary Table S4). The humoral immune
294response (involving genes such as LCN2, PGC, REG1A, ITLN1,
295BPIFB1, and BIRC3), digestive tract development (GATA6, ITGA6,
296CLDN18), and tissue homeostasis (LYZ, MUC6) were most signifi-
297cantly downregulated in these patients’ stroma, compared with
298patients with favorable outcome (Fig. 1C; Supplementary Table S4).
299Analysis of cancer samples from the same patients highlighted only 13
300DEGs, and no significant differentially regulated pathways (Supple-
301mentary Table S3; Supplementary Fig. S1H).
302The observed changes in stromal gene expression could be driven by
303differences in stromal abundance between the patient groups. To test
304this, we performed image analysis to quantify stroma, cancer, and
305immune regions in hematoxylin & eosin (H&E) stained FFPE sections
306from the patients.We found no significant difference in the percentage
307of stroma, cancer, and immune cells between the favorable and poor
308outcome patients, suggesting that it is not the abundance, but the
309transcriptional program that is different between the two groups
310(Supplementary Figs. S1I–S1L). These findings suggest that as tumors
311progress, stromal pathways involved in maintaining normal stomach
312functions are replaced by pathways resulting from tumor–stroma
313interactions that support tumor growth.
314Wenext set out to test the correlation between our stromal signature
315and clinical characteristics in independent datasets. Because no pure
316gastric CAFdatasetswith reported disease outcome are available, to the
317best of our knowledge, we turned to published datasets from bulk
CAFs Promote Gastric Cancer Via HSF1 and Exosomes
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The transcriptional landscape of gastric cancer stroma changes with disease aggressiveness. CAF-rich or cancer-rich regions of tumor sections from 9 patients with
gastric cancer were laser-capture microdissected and analyzed by RNA-seq. PCA was performed for (A) CAFs and (B) cancer cells. Purple/orange dots—survival/
lethality, as indicated. C, Heatmap showing hierarchical clustering of 129 genes differentially expressed in CAF-rich samples with favorable versus poor
outcome. Pathway analysis was performed using Metascape. Selected significant pathways (P < 0.05, FDR < 0.5) are shown (see Supplementary Table S4).
Purple/orange bars—survival/lethality, as indicated. D and E, Kaplan–Meier (KM) analysis showing overall survival of patients with (D) gastric or (E) colorectal
cancer from the TCGA stratified on the basis of median expression of the stromal gene signature (CAF_up_sig).Q5
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320 tumors and asked whether a stromal signature comprised of genes
321 upregulated in poor outcome patients in our dataset (CAF_up_sig)
322 could be detected in bulk tumors (including both stroma and
323 cancer cells). First, we analyzed The Cancer Genome Atlas (TCGA)
324 datasets for gastrointestinal (GI) tract cancers (gastric, colorectal,
325 pancreatic, hepatocellular, esophageal; Fig. 1D–E; Supplementary
326 Table S5), and found that the CAF_up_sig is significantly associated
327 with poor outcome in gastric cancer and in colorectal cancer (Fig. 1D
328 and E). Genes downregulated in the stroma (CAF_down_sig) did
329 not show any significant association with survival (Supplementary
330 Figs. S1M and S1N).
331 We then analyzed datasets from three other large patient cohorts:
332 The Singapore cohort, the KUGH_KUCM cohort, and the ACRG
333 cohort (Supplementary Table S6). CAF_up_sig expression significant-
334 ly associated with poor overall survival in the Singapore cohort and in
335 the KUGH_KUCM cohort, and a similar trend was found with the
336 ACRG cohort (Fig. 2A–C). Our CAF_down_sig showed an opposite
337 trend – high expression of CAF_down_sig significantly correlatedwith
338 favorable outcome in the Singapore andKUGH_KUCMcohorts, and a
339 similar mild trend was observed with the ACRG cohort (Fig. 2D–F).
340 Univariate analysis showed that CAF_up_sig expression, cancer stage,
341 and presence ofmetastasis were associatedwith poor overall survival in
342 the Singapore and the KUGH_KUCM cohorts and the ACRG cohort
343 showed a similar trend (Supplementary Table S6).
344 Wenext looked for potential associations between expression of our
345 CAF signature and gastric cancer subtypes. In all 3 patient datasets,
346 CAF_up_sig expression, but not CAF_down_sig expression, was
347 significantly enriched in the diffuse gastric cancer subtype, which
348 typically has a worse prognosis compared with the intestinal subtype
349 (Fig. 2G–I; Supplementary Figs. S2A–S2C). In addition to the
350 histologic classification of gastric cancer to diffuse and intestinal
351 subtypes, two independent molecular classification methods were
352 described recently (4, 5): A mesenchymal phenotype (MP) character-
353 ized by high genomic integrity and associated with poor survival, and
354 an epithelial phenotype (EP) characterized by low genomic integrity
355 and associated with favorable survival, were identified in the KUGH_-
356 KUCM cohort (5); and four molecular subtypes (MSS TP53–, MSS
357 TP53þ, MSI, EMT) were characterized in the ACRG cohort, of
358 which the EMT subtype was associated with the worst outcome (4).
359 Analyzing the KUGH_KUCM cohort, we found that the CAF_up_sig
360 was significantly enriched in theMP class, and the CAF-down_sig was
361 significantly enriched in the EP class (Fig. 2J). In theACRG cohort, the
362 CAF_up_sig was significantly enriched in the EMT subtype while the
363 CAF_down_sig was significantly enriched in MSS TP53þ/– subtypes,
364 associated with more favorable outcomes (Fig. 2K).
365 Supporting this classification, gene set enrichment analysis (GSEA)
366 using MSigDB (Hallmark gene sets, see Supplementary Materials and
367 Methods) on the full stromal RNA-seq dataset highlighted EMT as the
368 most significantly enriched pathway in patients with poor outcome
369 compared with patients with favorable outcome (Supplementary Figs.
370 S2D; Supplementary Table S7). These analyses collectively indicate
371 that the stromal signature correlates with diffuse, mesenchymal, and
372 aggressive gastric cancer subtypes, further reinforcing the clinical
373 relevance of our stromal classification and pointing to specific genes
374 for dissection and targeting.
375 A transcriptional signature derived from mouse PDPNþ gastric
376 CAFs is associated with aggressive gastric cancer phenotypes
377 and poor disease outcome in patients
378 To further dissect the contribution of CAFs to gastric cancer, we
379 induced gastric cancer in mice using a triple-transgenic gastric cancer
381mouse model- Lgr5-EGFP-IRES-CreERT2; R26-LSL-rtTA-IRES-
382EGFP; tetO-GLI2A mice, (iLgr5;GLI2A mice; ref. 21). This model is
383based on deregulated activation of the Hedgehog pathway by expres-
384sion of GLI2A, an activated form of GLI2, in Lgr5 expressing stem cells
385in the stomach (21).We isolatedCAFs and normal fibroblasts from the
386stomachs of gastric cancer-induced and na€ve iLgr5;GLI2A mice, and
387performed RNA-seq to obtain a pure mouse CAF transcriptional
388signature (Supplementary Table S8). To that end tumors were excised
3893 weeks after GLI2A induction, and CAFs were isolated by fluores-
390cence activated cell sorting (FACS) based on negative selection for
391CD45 (immune), EpCAM (epithelial), and CD31 (endothelial cells),
392and positive selection for PDPN (fibroblasts; Supplementary Fig. S3A;
393Supplementary Table S9; refs. 16, 28, 29). A total of 154 genes were
394differentially upregulated and 207were differentially downregulated in
395CAFs compared with normal gastric fibroblasts (Supplementary
396Table S8). Pathway analysis highlighted similar pathways to those
397discovered in the stromal dissection of the human patient samples:
398ECM organization (Adam12, Acan, Lox), activation of matrix metal-
399loproteinases (Mmp3, Mmp9, Mmp10, Mmp13), response to growth
400factors (Inhba, Grem1, Runx3), and regulation of hormone levels
401(Inhba, Cnr1, Cpe) were among the most differentially upregulated
402pathways in mouse CAFs, whereas digestion (Apoa1, Tff1, Pgc) and
403tissue homeostasis (Atp4a, Car2, Cldn18) were the most differentially
404downregulated pathways compared with normal gastric fibroblasts
405(Supplementary Table S10). We then checked whether a signature
406comprised of genes upregulated in mouse CAFs (mCAF_up_sig) or
407genes downregulated in mouse CAFs (mCAF_down_sig) would be
408associated with clinical characteristics in the Singapore, KUGH_-
409KUCM, and ACRG cohorts (Supplementary Table S11). Similar
410to the CAF_up_sig from patient samples, high expression of the
411mCAF_up_sig significantly associated with poor overall survival in
412the Singapore cohort and in theKUGH_KUCMcohort, and theACRG
413cohort showed a similar trend that was not statistically significant
414(Fig. 3A; Supplementary Figs. S3B and S3C). The mCAF_down_sig
415showed an opposite trend—it was significantly associated with favor-
416able outcome in the Singapore cohort and a similar trend was seen in
417the KUGH_KUCM cohort (Fig. 3A; Supplementary Fig. S3D). The
418ACRG cohort showed no particular trend for this analysis (Supple-
419mentary Fig. S3E). The mCAF_up_sig also correlated with the more
420aggressive MP and EMT molecular subtypes similar to the CAF_up
421signature from patient samples (Fig. 3B; Supplementary Fig. S3F),
422whereas the mCAF_down_sig correlated with the less aggressive EP
423and MSS TP53þ/– subtypes (Fig. 3B; Supplementary Fig. S3G). Col-
424lectively, the findings obtained from pure mouse CAFs support our
425findings from patient samples, indicate that CAFs support gastric
426cancer and provide potential targets and experimental systems for
427further characterization in mouse and human.
428INHBA and THBS1/2 are upregulated in gastric cancer stroma
429To characterize stromal pathways highlighted by our transcription-
430al profiling, we queried our patient gene list for potential interactions of
431translated proteins using STRING (Fig. 3C). On the basis of this
432analysis we chose to focus on two targets upregulated in poor outcome
433patients: inhibin Subunit Beta A (INHBA) and thrombospondin 2
434(THBS2), suggested to be part of a common signaling network (30).
435Both targets were recently found by us to be highly expressed in a
436subset of wound-healing CAFs in breast cancer (16). Moreover, they
437were both part of the EMTgene set highlighted by theGSEA analysis as
438enriched in patients with poor outcome (Supplementary Fig. S2D;
439Supplementary Table S7). We added to this analysis thrombospondin
4401 (THBS1), a close homologue of THBS2 that showed a similar trend of
CAFs Promote Gastric Cancer Via HSF1 and Exosomes
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High expression of the CAF signature is associated with aggressive disease and poor disease outcome in patients with gastric cancer. A–C, KM analysis showing
overall survival of patients from (A) the Singapore cohort; (B) the KUGH & KUCM cohort; and (C) the ACRG cohort stratified on the basis of expression of the
upregulated (CAF_up_sig) stromal gene signature. D–F, KM analysis showing overall survival of patients from the (D) Singapore cohort, (E) KUGH & KUCM cohort,
and (F) ACRG cohort stratified on the basis of expression of the downregulated (CAF_down_sig) stromal gene signature.G–I, Enrichment of the CAF_up_sig (mean
of normalized counts) in patients with diffuse versus intestinal gastric cancer in the (G) Singapore cohort; (H) KUGH & KUCM cohort; and (I) ACRG cohort.
J, Enrichment of the CAF_up_sig and CAF_down_sig (mean of the normalized counts) in patients with MP and EP subtypes in the KUGH & KUCM cohort (5).
K, Enrichment of the CAF_up_sig and CAF_down_sig (mean of normalized counts) in patientswithmolecular subtypes previously identified in the ACRG cohort (4).
One-way ANOVA was used in G–K.
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443 expression (Supplementary Table S3) and was also included in the
444 enriched EMT gene set (Supplementary Table S7). Inhba was differ-
445 entially upregulated also in mouse CAFs from iLgr5;GLI2A tumors,
446 and Thbs1/2 showed a similar trend (Fig. 3D–F). INHBA is a subunit
447 of Activin and Inhibin, dimeric proteins belonging to the TGFß
448 superfamily (31, 32). Activin A is a homodimer of two INHBA
449 subunits, whereas Inhibin A and Activin AB are heterodimers of
450 INHBAwith INHAand INHBB, respectively (32). INHBA is known to
451 play a role in inflammation, tissue repair, and activation of myofi-
452 broblasts, and increased levels of INHBA are associated with lymph
453 node (LN) metastasis, gastric cancer cell proliferation and chemore-
454 sistance (33). THBS1/2 are adhesive glycoproteins involved in cell–cell
455 and cell–matrix interactions. Increased levels of THBS2 are associated
456 with LN metastasis and increased invasion in gastric cancer (34). The
457 role of THBS1 is less clear since it was implicated both in pro- and
458 antitumorigenic activities in gastric cancer (35–37). Both INHBA and
459 THBS1/2 are known to play an important role in gastric cancer,
460 however their role in the TME is not well studied (30). To validate
461 our RNA-seq results, we extracted total RNA from iLgr5;GLI2A
462 tumors and examined the levels of Inhba, Thbs1, and Thbs2 by qPCR.
463 Inhba andThbs1 levels were significantly upregulated in gastric tumors
464 compared with normal gastric tissue andThbs2 showed a similar trend
465 (Fig. 3G–I). To define the tissue localization of INHBA and THBS1/2,
466 and confirm their expression at the protein level, we performed IHC
467 staining of sections from iLgr5;GLI2A tumors and from normal
468 stomach controls using antibodies against INHBA and THBS1.
469 INHBA and THBS1 were expressed at very low levels in normal
470 gastric glands and muscle (Fig. 3J and K). Gastric tumors, however,
471 exhibited high levels of INHBA and THBS1 both in stroma and in
472 cancer cells (Fig. 3J and K). Together, these findings support our
473 patient RNA-seq results and suggest that INHBA and THBS1/2 are
474 upregulated in gastric cancer stroma.
475 Given their connectivity to other genes in the stromal network
476 revealed by the STRINGanalysis (Fig. 3C), and the potential simplicity
477 of a 3-gene signature (compared with a signature comprised of dozens
478 of genes), we tested whether a minimal gene signature comprised of
479 only INHBA and THBS1/2 would correlate with disease outcome in
480 our patient datasets. We found that the 3-gene signature (INHBA/
481 THBS1/THBS2) correlated with poor disease outcome in the TCGA
482 gastric cancer and colorectal cancer datasets, the Singapore cohort, and
483 the KUGH_KUCM cohort (Supplementary Figs. S4A–S4D; Supple-
484 mentary Table S6). As with the other stromal signatures that we
485 analyzed, the ACRG cohort showed a similar trend of disease outcome
486 that was not statistically significant (Supplementary Fig. S4E), possibly
487 due to differences in patient follow up time or cohort characteristics
488 (Supplementary Table S6). These results imply that stromal INHBA
489 and THBS1/2 are associated with aggressive disease phenotypes in
490 gastric cancer, and serve as attractive targets for characterization.
492HSF1 activation in gastric CAFs is associated with poor disease
493outcome
494In search for potential transcriptional regulators of the stromal
495signature in general, and INHBA and THBS1/2 in particular, we
496examined heat-shock factor 1 (HSF1). Previously, we and others have
497shown that HSF1, the master transcriptional regulator of the heat
498shock response, plays an important role in the conversion offibroblasts
499into CAFs in the TME (20, 38). Moreover, INHBA and THBS1 were
500shown to be transcriptional targets of HSF1 (39, 40). In gastric cancer,
501activation of HSF1 in cancer cells was shown to correlate with poor
502disease outcome (41), yet the contribution of stromal HSF1 to disease
503outcome has not been assessed. HSF1 translocates from the cytoplasm
504to the nucleus and binds to heat shock elements in the DNA upon
505activation (39). Therefore, its nuclear localization is commonly used as
506a proxy for HSF1 activation (39). Indeed, IHC staining of FFPE
507sections from patients with gastric cancer revealed nuclear HSF1
508staining both in cancer cells and in CAFs, whereas normal stomach
509glands and muscle exhibited low or no HSF1 staining (Fig. 4A).
510To systematically test whether stromal activation of HSF1 is asso-
511ciated with disease outcome in gastric cancer, we performed IHC
512staining forHSF1 and scored its nuclear localization in cancer cells and
513CAFs, in sections from 64 patients with gastric cancer (including the
514subcohort of LCM–RNA-seq patients) with documented clinical
515characteristics and patient outcome data (Supplementary Table S1).
516High HSF1 activation in cancer cells correlated with shorter overall
517survival time and stromalHSF1 showed a similar trend (Fig. 4B andC;
518Supplementary Table S12). In the cohort of patients analyzed by LCM
519and RNA-seq, all patients with poor outcomes also exhibited inter-
520mediate or high HSF1 activation (i.e., nuclear localization) in cancer
521and stromal cells, whereas patients with favorable outcomes differed in
522their HSF1 activation status (Supplementary Table S1). Interestingly,
523stromal HSF1 activation also significantly correlated with HER2 status
524—HER2– patients exhibited highHSF1 levels whereas HER2þ patients
525had low stromal HSF1 activation levels (Supplementary Table S1).
526These results imply that in addition to its previously described roles
527in gastric cancer cells, HSF1 activates complementary pathways in
528gastric stroma that promote aggressive disease phenotypes. This
529conclusion was further supported by a multivariate Cox proportional
530hazards regression analysis (Supplementary Table S12). In an additive
531multivariate model considering tumor stage and HSF1 score, stromal
532HSF1 score and tumor stage were significantly associated with overall
533survival (P ¼ 0.006), and this association was more significant than
534that of cancer HSF1 and tumor stage with survival (P ¼ 0.016).
535Stromal INHBA and THBS1/2 are targets of HSF1, in vitro
536Multiplexed immunofluorescent staining (MxIF) of patient with
537gastric cancer samples showed that HSF1 is co-expressed with INHBA
538and THBS1, in cancer cells and in CAFs, whereas normal stomach
Figure 3.
INHBA and THBS1/2 are upregulated in gastric cancer. A and B, Gastric cancer was induced in iLgr5;GLI2A mice, PDPNþ fibroblasts were isolated from the resulting
tumors and RNA-seqwas performed using fibroblasts isolated from stomachs of na€vemice as control. Signatures comprised of genes upregulated (mCAF_up_sig;)
or downregulated (mCAF_down_sig) in PDPNþ CAFs vs. PDPNþ normal fibroblasts were derived. A, KM analysis of overall survival in patients from the Singapore
cohort stratifiedon the basis of expression of themCAF_up_sig (left) ormCAF_down_sig (right).B,Enrichment of themCAF_up_sig andmCAF_down_sig (meanof
normalized counts) in patients with the MP and EP subtypes in the KUGH & KUCM cohort. One-way ANOVA was used for statistical analysis. C, STRING analysis of
potential interactionsbetweenprotein products of genes differentially expressed inpatientswith gastric cancerwith favorable versus poor outcome. Proteinswith no
connections were omitted from the image. THBS2 and INHBA are highlighted in red.D–F, Log-normalized counts and P-adjusted values of the indicated genes taken
from DESeq analysis of the iLgr5;GLI2A PDPNþ CAF RNA-seq data (Supplementary Table S8). G–I, Total RNA levels of the indicated genes normalized to HPRT in
normal stomachs and tumors (cancer) from iLgr5;GLI2A mice. N¼ 3 mice per group, means SEM are presented. Two-tailed Student t test was used for statistical
analysis. J–K, Representative images showing H&E and immunohistochemical staining of the indicated proteins in gastric tumors and control stomachs (na€ve) from
iLgr5;GLI2Amice.N¼ 5mice for cancer andN¼ 3mice for normal control. C, cancer; S, stroma. Scale bar¼ 100 mm. Arrows indicate INHBA and THBS1 positive CAFs.
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Figure 4.
HSF1 is co-expressed with INHBA and THBS1 in human gastric CAFs. A, FFPE sections from 64 patients with gastric cancer and four normal controls
were stained by H&E and IHC staining for HSF1. (Top) Images representing high (pt 6) versus low (pt 18) nuclear HSF1 staining in CAFs. (Bottom)
Representative images of normal gastric glands and muscle. C, cancer; S, stroma. Scale bar ¼ 100 mm. B and C, 64 gastric cancer samples stained as described
above were scored for high/intermediate (int)/low nuclear HSF1 staining in cancer cells/CAFs, and KM analysis of overall survival in these patients was
performed. B, Patients were stratified by high versus int/low HSF1 scores in cancer cells. C, Patients were stratified by high/int versus low HSF1 scores in CAFs
(see Supplementary Table S1). D, FFPE sections from 4 patients with gastric cancer and 2 normal stomach controls were stained by multiplexed
immunofluorescence for HSF1, INHBA, THBS1, and DAPI (nuclear marker). Representative images from 3 different patients and one control are shown.
Scale bar ¼ 50 mm.
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Stromal INHBAandTHBS1/2 expression is HSF1-dependent.A–E, INHBA, THBS1, andTHBS2protein expression levels inWTandHsf1null primaryMEFswere analyzed
byWestern blot analysis. Representative blots are shown inA andB. An arrow indicates the expected size of INHBAbands.C, INHBAWestern blot analysis results of 5
to 10 biological replicates (across two experiments) were quantified, normalized to actin, and are presented as mean  SEM. D and E, THBS1 Western blot analysis
results of five biological replicates (across two experiments) and THBS2Western blot analysis results of 5 to 10 biological replicates (across three experiments) were
quantified, normalized to actin, and are presented asmean SEM. Two-tailed Student t test was used for statistical analysis inC–E. F–K,WT andHsf1 null MEFswere
co-culturedwithN87-GFP cells for 72 hours, and each cell typewas grown inmono-culture as control. Co-cultureswere sorted byflowcytometry usingGFP.F–H, The
levels of the indicated genes in (GFP-negative)MEFswere determinedby qPCR. Average expression in six to eight biological replicates (across three experiments for
INHBA and THBS1 and two experiments for THBS2), normalized to HPRT, SEM are presented. Two-way ANOVA was used for statistical analysis. I, Representative
GFP (top), and brightfield (bottom) images ofmono and co-cultures are shown.N¼ 3 biological replicates. Scale bar¼ 50 mm. J,Representative FACS plots showing
the percentage ofN87-GFP cells co-culturedwithWT (left) andHsf1nullMEFs (right).N¼ 3biological replicates.K,The averagepercentage (SEM) ofN87-GFP cells
co-cultured with WT and Hsf1 null MEFs in three biological replicates is shown. Two-tailed Student t test was used for statistical analysis. L–N, HFF cells treated with
siHSF1, siINHBA, siHSF1-INHBA-THBS2 (siCombined), or siControl as indicated were co-cultured with N87-GFP cells for 72 hours. The percentage of N87-GFP in the
co-cultures averaged across five to nine biological replicates (SEM; across three experiments for siINHBA and siHSF1-INHBA-THBS2 and two experiments for
siHSF1) is shown. Two-tailed Student t test was used for statistical analysis.
Grunberg et al.


































































































































MC38 only (n = 8)
MC38 + THBS2 (n = 8)
MC38 + Activin A (n = 8)
P = 0.009

















MC38 only (n = 15)
MC38 + WT EVs (n = 14)
MC38 + Hsf1 null EVs 



















Fibroblast-derived EVs promote tumor growth in an HSF1-dependent manner. A, Nude mice were injected subcutaneously with MC38 cancer cells alone, or co-
injectedwith either recombinant THBS2 orActivinA followedby another injection of recombinant protein 2 days later. Tumor sizemeasuredby caliper is presented as
mean  SEM for N ¼ 8 mice per group (across two experiments). Repeated measures two-way ANOVA using least-squares means to adjust for group pairwise
comparisons was used for statistical analysis. B and C,Western blot analysis of fractions obtained from Optiprep density gradient isolation of EVs secreted by WT
MEFs blotted against exosomal markers ALIX and TSG101, as well as THBS1/2, INHBA, and HSF1. EVs from three WT MEFs were pooled together for the isolation.
The experiment was repeated twice (with different biological replicates), representative results are shown. D, Representative TEM images of low (i–ii) and high
(iii) density EV fractions (repeated two times, from two biological replicates). (Continued on the following page.)
CAFs Promote Gastric Cancer Via HSF1 and Exosomes
AACRJournals.org Cancer Res; 2021 11
541 tissue exhibited low INHBA, THBS1, and HSF1 staining (Fig. 4D). To
542 test whetherHSF1 regulates INHBA andTHBS1/2 stromal expression,
543 and whether this regulation affects cancer cells, we measured the
544 expression of INHBA and THBS1/2 in WT versus Hsf1 null mouse
545 embryonic fibroblasts (MEF). THBS1/2 and INHBA protein levels
546 were significantly higher inWTMEFs compared withHsf1 null MEFs
547 (Fig. 5A–E). Next, we asked if INHBA and THBS1/2 expression in
548 fibroblasts is affected by co-culture with cancer cells. Seventy-two
549 hours of co-culture with N87 human gastric cancer cells led to a
550 significant increase in Inhba, Thbs1, and Thbs2 mRNA levels com-
551 pared with cells grown in mono-culture (Fig. 5F–H). Some induction
552 was also observed in Hsf1 null MEFs upon co-culture, however the
553 total levels were lower in Hsf1 null MEFs compared with WT MEFs
554 (Fig. 5F–H).
555 To determine how this stromal network affects cancer cells, we
556 monitored cancer cell growth in co-culture. N87 cells showed a
557 significant growth reduction when co-cultured with Hsf1 null MEFs
558 compared with WT MEFs (Fig. 5I–K), and similar results were
559 observed upon co-culture of N87 cells with human foreskin fibroblasts
560 (HFF) in which HSF1 was knocked down by siRNA (Fig. 5L; Sup-
561 plementary Figs. S5A–S5C).
562 Next, we knocked down INHBA, THBS1, and THBS2 in fibroblasts
563 andmonitored gastric cancer cell growth in co-culture. Knockdown of
564 THBS2 in HFFs led to a minor decrease in N87 cell proliferation, and
565 knockdown of THBS1 led to a minor increase in N87 proliferation
566 (Supplementary Figs. S5D–S5F). Knockdown of INHBA however led
567 to a substantial and significant decrease in the growth of co-cultured
568 N87 cells (Fig. 5M; Supplementary Fig. S5G). A combined knockdown
569 ofHSF1–INHBA–THBS2had a similar effect onN87 growth (Fig. 5N),
570 whereas the combination of HSF1 and INHBA with THBS1 had a
571 milder effect (Supplementary Fig. S5H). Collectively, these results
572 support the hypothesis that HSF1, INHBA, and THBS1/2 are part of
573 a common stromal protumorigenic signaling network, in which HSF1
574 regulates the expression of THBS1/2 and INHBA. Although INHBA
575 and THBS2 seem to play a protumorigenic role in fibroblasts, THBS1
576 may be antitumorigenic.
577 THBS2 and INHBA are secreted from fibroblasts via EVs, in an
578 HSF1-dependent manner
579 INHBA and THBS1/2 are secreted proteins (42). We therefore
580 hypothesized that INHBA and THBS2 are secreted from CAFs to the
581 TME where they act on cancer cells, and that this process could be
582 mimicked by exogenous treatment with recombinant proteins. To test
583 this, we co-injected MC38 colon cancer cells with recombinant
584 proteins into mice, subcutaneously, followed by another injection of
585 recombinant protein 2 days later, and monitored tumor growth. Co-
586 injection of either THBS2 or Activin A (a homodimer of two INHBA
587 subunits; ref. 31) with MC38 cancer cells significantly increased the
589tumorigenicity of these cells—larger and faster growing tumors
590formed in the presence of THBS2 or Activin A (Fig. 6A).
591INHBA and THBS1/2 have been proposed to shuttle through
592EVs (43–49). Recently, THBS2was shown to be amarker for exosomes
593secreted by tumors (50). We therefore hypothesized that the protu-
594morigenic effects of stromal HSF1 may be mediated by secretion and
595delivery of these proteins to the TME, possibly via EVs. Small EVs are
596lipid bilayer-enclosed particles sized 30 to 150 nm, whichmediate cell–
597cell communication via targeting, fusion, and release of content from
598one cell to another (51). Their cargo includes bioactive molecules such
599as effector proteins, metabolites, large and small RNAs, and even
600genomic DNA (50). Recently, EVs secreted from stromal cells were
601shown to contribute to disease progression and poor disease outcome
602by promoting vascularization and chemotherapy resistance (52). To
603test whether INHBA and THBS1/2 are secreted via EVs in an HSF1-
604dependent manner, we first confirmed the presence of INHBA and
605THBS1/2 in EVs by OptiPrep density gradient isolation of EVs
606secreted from WT MEFs (Fig. 6B and C; Supplementary Fig. S6A).
607ALIX andTSG101, two known exosomemarkers, were used as positive
608loading controls (53). HSF1 is not expected to be found in EVs and
609therefore served as a negative control. ALIX andTSG101were found in
610fractions 3 to 8. Both proteins peaked in high density fractions (6–7),
611and TSG101 had an additional peak in low density fraction 4 (Fig. 6B
612and C). HSF1 was not detected in any of these fractions. INHBA and
613THBS1/2, however, were detected in fractions 2 to 7, and peaked in
614fractions 4 to 5 (Fig. 6B andC). To confirm that these fractions contain
615EVs, we performed transmission electron microscope (TEM) analysis.
616We found that EVs are indeed observed in both low- and high-density
617fractions (Fig. 6D). These observations suggest that two populations of
618EVs are secreted by MEFs—a low-density population, enriched in
619INHBA and THBS1/2 (Supplementary Fig. S6A) and a high-density
620populationwith lower levels of INHBAandTHBS1/2.We also checked
621the presence of INHBA and THBS1/2 in EVs isolated from the serum
622of iLgr5;GLI2A mice. Although we could not detect THBS1/2 in the
623serum (possibly due to low sensitivity of the assay), INHBA was
624detected, and its levels were significantly higher in EVs isolated from
625the serum of tumor-bearing iLgr5;GLI2A mice compared with EVs
626isolated from the serum of na€ve iLgr5;GLI2A mice (Fig. 6E and F).
627We then compared the expression levels of INHBA and THBS1/2 in
628EVs isolated from WT versus Hsf1 null fibroblasts. Although THBS1
629levels were similar between WT and Hsf1 null-derived EVs, THBS2
630and INHBA levels were significantly higher in EVs derived from WT
631MEFs compared with EVs from Hsf1 null MEFs (Fig. 6G–J). These
632results suggest that INHBA and THBS2 expression in EVs is HSF1-
633dependent.
634To examine whether the differential expression of INHBA and
635THBS2 was due to impaired EV biogenesis in Hsf1 null MEFs, we
636compared the number and size of EVs produced by each genotype
(Continued.) (i) 1.03% sucrose; (ii) 1.04% sucrose; (iii) 1.07% sucrose. Scale bars¼ 100 nm. E, Representative Western blot analysis showing INHBA levels from EVs
isolated from the serumof tumor-bearing and na€ve iLgr5;GLI2Amice. ALIX was used as loading control. Arrow indicates expected size of ALIX. F, INHBA levels from
EVs isolated from the serumof tumor-bearing andna€ve iLgr5;GLI2Amicewere analyzedusingWestern blot analysis. INHBA levelswere normalized toALIX. Average
expression of INHBA normalized to ALIX in five biological replicates (across two experiments) is presented in asmean SEM. Two-tailed Student t test was used for
statistical analysis. G–J, INHBA, THBS1, and THBS2 levels in EVs derived from WT and Hsf1 null primary MEFs were analyzed using Western blot analysis. ALIX and
TSG101 were used as loading controls. Representative blots are shown in G. H, Average expression of INHBA normalized to TSG101 in eight biological replicates
(across three experiments for INHBA) is presented asmean SEM. I,Average expression of THBS1 normalized to TSG101 in five to seven biological replicates (across
three experiments) is presented as mean  SEM. J, Average expression THBS2 normalized to TSG101 in 10 to 11 biological replicates (across four experiments) is
presented as mean SEM. Two-tailed Student t test was used for statistical analysis in H and I. K, Nude mice were injected subcutaneously with MC38 cancer cells
alone, or co-injectedwith EVs derived fromWTorHsf1 null MEFs. Tumor sizemeasured by caliper is presented asmean SEM forN¼ 14 to 15mice per group (across
four experiments). Repeated measures two-way ANOVA using least-squares means to adjust for group pairwise comparisons was used for statistical analysis.
L, Graphic summary of the proposed model. HSF1 in CAFs regulates expression of INHBA and THBS1/2. INHBA and THBS2 from CAFs are packaged into EVs and
secreted to the TME, where they are taken up by cancer cells.
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639 using nanoparticle tracking analysis (NTA). We could not detect
640 differences in size or in quantity between EVs secreted from WT and
641 Hsf1 null fibroblasts (Supplementary Figs. S6B–S6E).We extended our
642 analysis to field-flow fractionation (FFF), to better separate EV popu-
643 lations and assess smaller EV populations shown to be biologically
644 active (54). Similar to our NTA analysis, FFF did not detect consistent
645 differences between EVs derived fromHsf1 null MEFs compared with
646 WT MEFs (Supplementary Fig. S6F). We next tested whether the
647 differences in protein content could be due to impaired uptake of EVs
648 derived from Hsf1 null compared with WT MEFs. We incubated
649 N87 gastric cancer cells and MC38 colon cancer cells with CFSE
650 stained EVs, and analyzed uptake 12 to 16 hours later by imaging the
651 cells in an ImageStream imaging flow cytometer. We could not detect
652 differences in the percentage of CFSEþN87 andMC38 cells incubated
653 in the presence of EVs from Hsf1 null compared with WT MEFs
654 (Supplementary Figs. S6G–S6O), indicating that HSF1 does not affect
655 EV biogenesis or uptake, yet it plays an important role in the protein
656 content of EVs.
657 To assess the biological relevance of these findings we co-injected
658 EVs derived from WT versus Hsf1 null MEFs together with MC38
659 cancer cells into nude mice, and monitored tumor growth. Co-
660 injection with EVs derived from WT MEFs caused a significant
661 increase in the growth of MC38-injected tumors (Fig. 6K). This effect
662 was completely abolished when EVs from Hsf1 null MEFs were co-
663 injected with MC38 cells. Taken together these experiments show that
664 EVs derived fromWT andHsf1 nullMEFs are similar in size, quantity,
665 biogenesis, and uptake into cancer cells. However, there is a significant
666 difference in their content and, consequently, their effect on tumor
667 growth. These findings imply that HSF1 regulates the expression of
668 INHBA and THBS1/2 in stromal cells. INHBA and THBS2 are then
669 packaged into EVs in an HSF1-dependent manner and secreted to the
670 TME, where they are taken up by cancer cells and promote a more
671 aggressive disease phenotype (Fig. 6L).
672 Discussion
673 Despite recent advances in molecular subtyping, the backbone of
674 gastric cancer treatment remains chemotherapeutic combinations.
675 Molecular classifications, based largely on mutations and genomic
676 alterations in the cancer cells, do not translate to guide treatment
677 modality. Here we chose a complementary approach—searching for
678 transcriptional changes in the gastric TME.We defined a stromal gene
679 signature associated with poor disease outcome in patients, and found
680 a role for the stromal master transcriptional regulator HSF1 in driving
681 it, through exosome-mediated secretion of protumorigenic proteins
682 that are taken up by cancer cells to promote aggressive disease
683 phenotypes.
684 HSF1 was previously shown by us and others to play protumori-
685 genic roles in CAFs of breast, lung, and colon carcinomas (17, 20, 38).
686 The finding that HSF1 also acts in gastric CAFs implicates HSF1 as a
687 master regulator of CAF activities in carcinomas across different
688 tissues, and suggests that its protumorigenic effects—in gastric cancer
689 and other carcinomas—may be mediated via delivery of targets to the
690 TME in EVs.
691 INHBA and THBS1/2 are involved in tumor progression and were
692 shown to be co-regulated (30, 55, 56) possibly sharing common
693 signaling pathways. Although INHBA and THBS2 are protumori-
694 genic, THBS1 was proposed to exert both pro- and antitumorigenic
695 effects, depending on the system examined (44, 55, 57). Our findings
696 suggest that all three proteins are upregulated in CAFs in an HSF1-
697 dependent manner. Our in vitro experiments andmouse co-injections
699with recombinant proteins show a clear protumorigenic role of Activin
700A and THBS2, whereas the effect of stromal THBS1 on cancer cells
701(in vitro) is less clear. Taken together with the finding that INHBA and
702THBS2 are delivered into exosomes in an HSF1-dependent manner,
703whereas THBS1 exosomal expression is not affected by HSF1 status, it
704is possible that selective delivery of INHBA and THBS2 to exosomes
705leads to the protumorigenic effect observed, whereas THBS1 is
706antitumorigenic.
707EV cargo includes proteins, metabolites, RNA, and genomic
708DNA (50), which could serve as bioactive molecules in the TME. In
709GI-tract cancers, EVs from CAFs were shown to promote cancer
710through delivery of miRNAs to gastric cancer cells to suppress
711ferroptosis (58), and Wnt glycoproteins to colorectal cancer cells to
712induce cancer stemness and chemoresistance (59). In our study,
713differential protein expression in EVs affects their activity. Although
714biogenesis and uptake of EVswas not impaired, loss of HSF1 abolished
715the protumorigenic effect of EVs derived fromWTMEFs.Ourfindings
716indicate that EV cargo is selective and the content is affected by HSF1.
717Over the last years, efforts were made to identify gastric cancer
718drivers and gene signatures that may serve as biomarkers for diagnosis
719and treatment (3). Trastuzumab revolutionized the treatment of
720HER2-positive gastric cancers (60), and immunotherapy has proven
721to be an effective therapy for patients with microsatellite instability
722(MSI; ref. 61). Other signatures, such as those associated with Heli-
723cobacter pylori and EBV infections (62, 63), germline mutations of
724CDH1, mismatch repair genes (64, 65), epithelial versus mesenchymal
725cell types (5), and MSS TP53–, MSS TP53þ, MSI, EMT subtypes (4)
726enabled associations between molecular landscape and gastric cancer
727subtyping (3, 60). However, the TME of gastric cancer in general, and
728the molecular composition of gastric CAFs in particular, have been
729scarcely studied. Our profiling of CAFs from patient tumors highlights
730stromal compositions associated with the aggressive diffuse and EMT-
731like gastric cancer subtypes. These targets should be further explored,
732certainly as prognostic targets and hopefully as robust therapeutic
733targets in gastric cancer.
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